Country: Malta
Lingwa: Ingliż
Sors: Medicines Authority
fluorometholone acetate 1 mg/ml
S.A Alcon-Couvreur N.V.
S01BA07
fluorometholone acetate
eye drops, suspension
Authorised
2005-09-07
PATIENT INFORMATION LEAFLET READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. • _Keep this leaflet. You may need to read it again._ • _If you have further questions, please ask your doctor or your pharmacist._ • _This medicine has been prescribed for you personally and you should not pass it _ _on to others. It may harm them, even if their symptoms are the same as yours._ CONTENTS OF THIS LEAFLET 1. What FLAREX is and what it is used for. 2. What you should know before you use FLAREX. 3. How to use FLAREX. 4. Possible side effects. 5. How to store FLAREX. 6. Further information. FLAREX, 1mg/ml, eye drops, suspension Fluorometholone acetate - The active substance is fluorometholone acetate 1.0 mg/ml. - The other ingredients (excipients) are benzalkonium chloride 0.1 mg, disodium edetate, monobasic sodium phosphate monohydrate,, tyloxapol, sodium chloride, hydroxyethylcellulose, concentrated hydrochloric acid and/or sodium hydroxide and purified water to 1 ml. MARKETING AUTHORISATION HOLDER AND MANUFACTURER SA Alcon-Couvreur NV Rijksweg 14 2870 Puurs MARKETING AUTHORISATION NUMBER MA 015/00401 1. WHAT FLAREX IS AND WHAT IT IS USED FOR FLAREX, eye drops, suspension is packed in a 5, 10 and 15 ml droptainer. FLAREX is a corticosteroid for the treatment of eye inflammations. FLAREX is indicated for the treatment of inflammations of the conjunctiva, cornea and the anterior segment of the eye, if these inflammations react to corticosteroids and are not caused by germs. 1 Aqra d-dokument sħiħ
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT FLAREX, 1 mg/ml, eye drops, suspension. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fluorometholone acetate 1.0 mg/ml. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Eye drops, suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of steroid-responsive, non-infectious inflammations of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eye. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Shake well before using. Adults: 1 to 2 drops in the conjunctival sac 4 times daily. During the initial 48 hours the dosage may be safely increased to 2 drops every 2 hours. If there is no improvement after 2 weeks, consult the physician. Care should be taken not to discontinue therapy prematurely. Children: FLAREX is usually not recommended for pediatric use since its safety and effectiveness have not been established. Elderly: There are no special precautions to be followed. If used in patients with glaucoma, treatment should be limited to 2 weeks, unless longer treatment is justified (see 4.3 Contraindications and 4.4 Special warnings and special precautions for use). 4.3 CONTRAINDICATIONS • Hypersensitivity to the active substance or to any of the excipients • Acute, untreated bacterial infections Page 1 of 7 • Herpes simplex keratitis • Vaccinia, varicella, and other viral infections of cornea or conjunctiva • Fungal diseases of ocular structures • Mycobacterial ocular infections 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE Not for injection. The extensive and/or prolo Aqra d-dokument sħiħ